Figure 2From: Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer PFS (A) and OS (B) of patients with VEGF -1498 T/T versus -1498 C-genotype in the bevacizumab-group (N = 111).Back to article page